Angeles Wealth Management LLC Sells 23 Shares of Medpace Holdings, Inc. $MEDP

Angeles Wealth Management LLC lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 908 shares of the company’s stock after selling 23 shares during the period. Angeles Wealth Management LLC’s holdings in Medpace were worth $285,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Oxbow Advisors LLC raised its stake in shares of Medpace by 3.6% during the 2nd quarter. Oxbow Advisors LLC now owns 9,188 shares of the company’s stock worth $2,884,000 after acquiring an additional 323 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Medpace by 4.8% during the 2nd quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock worth $19,067,000 after acquiring an additional 2,792 shares in the last quarter. Empirical Asset Management LLC raised its stake in shares of Medpace by 29.9% during the 2nd quarter. Empirical Asset Management LLC now owns 1,993 shares of the company’s stock worth $626,000 after acquiring an additional 459 shares in the last quarter. Boston Trust Walden Corp increased its stake in Medpace by 12.1% during the 2nd quarter. Boston Trust Walden Corp now owns 151,074 shares of the company’s stock valued at $47,416,000 after purchasing an additional 16,270 shares in the last quarter. Finally, TD Asset Management Inc increased its stake in Medpace by 15.6% during the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock valued at $143,636,000 after purchasing an additional 61,764 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total value of $4,800,000.00. Following the sale, the vice president owned 57,500 shares in the company, valued at $27,600,000. This represents a 14.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total transaction of $772,896.48. Following the sale, the director directly owned 10,197 shares in the company, valued at $4,742,012.88. This trade represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

MEDP has been the topic of a number of recent analyst reports. Mizuho upped their price target on shares of Medpace from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 22nd. Barclays upped their price target on shares of Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft upped their price target on shares of Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. Finally, UBS Group lowered shares of Medpace from a “neutral” rating to a “sell” rating and upped their price target for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Reduce” and a consensus target price of $430.60.

Medpace Price Performance

NASDAQ:MEDP opened at $528.07 on Friday. The firm has a market capitalization of $14.83 billion, a P/E ratio of 39.26, a PEG ratio of 3.27 and a beta of 1.40. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $547.15. The company’s fifty day moving average price is $492.23 and its 200-day moving average price is $381.83.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.